N-methyl-N-(1-methylpiperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]propanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-N-(1-methylpiperidin-4-yl)-3-[4-(trifluoromethyl)phenyl]propanamide
• 化学式: C₁₇H₂₃F₃N₂O
• 分子量: 328.37
• InChiKey: IZKFBPRVXJEYBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Compounds and Methods for the Treatment of Viruses and Cancer
  申请人：Jorgensen William L.

  公开号：US20100222352A1

  公开（公告）日：2010-09-02

  The present invention relates to compounds according to the formula I: Where R a is H or an optionally OH-substituted C 1 -C 3 alkyl; R 1 is OR 1 , an optionally substituted C 4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R 1 is an optionally substituted C 1 -C 14 hydrocarbyl group or an optionally substituted heterocyclic group; R 2 , R 3 and R 4 are each independently H, an optionally substituted C 1 -C 4 alkyl group (preferably CH 3 , CH 2 CH 3 or CF 3 ), halogen (preferably F, Cl, Br), OR, CN, NO 2 , a C 1 -C 6 thioether, a C 1 -C 6 thioester group, an optionally substituted CO 2 R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R 4 is H); R is H or an optionally substituted C 1 -C 6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.

  本发明涉及公式I的化合物：其中R为H或可选择的OH取代的C1-C3烷基; R1为OR1，可选择取代的C4-12碳环基，可饱和或不饱和（包括芳香族）或可选择取代的杂环基; R1为可选择取代的C1-C14烃基或可选择取代的杂环基; R2、R3和R4各自独立地为H、可选择取代的C1-C4烷基（优选为CH3、CH2 或CF3）、卤素（优选为F、Cl、Br）、OR、CN、NO2、C1-C6硫醚、C1-C6硫酯基、可选择取代的CO2R基团、可选择取代的COR基团或可选择取代的OCOR基团（优选R4为H）; R为H或可选择取代的C1-C6烷基; RHET为可选择取代的杂环基;以及其药学上可接受的盐、溶剂或多晶体。
• SUBSTITUTED PIPERIDINES
  申请人：Dorwald Florencio Zaragoza

  公开号：US20100222386A1

  公开（公告）日：2010-09-02

  A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

  一种新的取代哌啶类化合物、包含它们的药物组合物和在治疗和/或预防与组胺H3受体相关的疾病和紊乱方面的应用。更具体地说，这些化合物可用于治疗和/或预防与组胺H3受体相互作用有益的疾病和紊乱。
• SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR
  申请人：High Point Pharmaceuticals, LLC

  公开号：EP1434765B1

  公开（公告）日：2009-12-02
• US7767695B2
  申请人：——

  公开号：US7767695B2

  公开（公告）日：2010-08-03
• US9018209B2
  申请人：——

  公开号：US9018209B2

  公开（公告）日：2015-04-28